Immuno-Oncology 2019

Topics

• The recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
• Targeting immune checkpoints with Humabody VH Therapeutics
• Unwanted immunogenicity and functionality testing of immuno-oncology drugs
• The tumour mutation burden and the potential of its use as an indication of treatment choice
• New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Who should Attend

Attendees with job titles such as:

• Director of Immunopharmacology
• Professor of Immunochemistry, Oncology, Experimental Immunology, Cancer Medicine and Medicinal Oncology
• Scientist, Tumour Immunology
• Medical Assessor, Biologics Licensing
• Director of Research
• Head of Clinical Analysis
• Head of Immunology
• Consultant in Medical Oncology